Braxia Scientific Provides Update on Large Proprietary Dataset Expected to Support Pharmaceutical and Industry Clinical Trials for Ketamine and Psilocybin Drug Development
TORONTO, ONTARIO January 31, 2022 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today provided an update on the Company’s leading research role within the psychedelics industry. As the Company continues to focus on developing innovative treatments for depression, including potential ketamine derivatives, Braxia Scientific’s team of researchers also continue to carry out multiple psychedelic-based clinical research trials, adding to the Company’s large and growing proprietary dataset critical to informing future drug development. To date, Braxia Scientific has compiled comprehensive health data from administering more than 5,200 ketamine treatments at its network of clinics. Additionally, Braxia Scientific’s researchers have published 43 ketamine-related manuscripts in peer-reviewed biomedical journals, and the Canadian Rapid Treatment Centre of Excellence (CRTCE), a wholly owned Braxia...
Landmark Clinical Trial
BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE AUGUST 10-12 TORONTO, ONTARIO Aug. 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Canaccord Genuity Annual Growth Conference. The conference will be held virtually on August 10-12, 2021. Braxia Scientific CEO Dr. Roger McIntyre will deliver a presentation on the company’s initiatives related to developing novel therapeutics and delivery systems for treating depression and other brain-based disorders, as well as its administration of patient care in its network of clinics. Presentation Details: Date: Tuesday, August 10, 2021 Time: 11:30 a.m. ET Event Registration: https://bit.ly/3josIt3 For additional information on the conference, please CLICK HERE. About Braxia Scientific Corp. Braxia Scientific is a...
PSYCHEDELICS IN PSYCHIATRY AND BEYOND
BRAXIA SCIENTIFIC TO PRESENT AT THE PSYCHEDELICS IN PSYCHIATRY AND BEYOND VIRTUAL CONFERENCE HOSTED BY H.C. WAINWRIGHT & CO. ON JUNE 17, 2021 TORONTO, ONTARIO June 9, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Psychedelics in Psychiatry and Beyond Virtual Conference, hosted by H.C. Wainwright & Co. on June 17, 2021. Braxia’s CEO, Dr. Roger McIntyre will present and participate in a panel discussion, “Patient Experience And Commercial Considerations When Launching Psychoactive Agents In Psychiatry.” Dr. McIntyre will also be available to host virtual one-on-one meetings with institutional investors registered with H.C. Wainwright and Co. For additional information on the conference please visit: https://hcwevents.com/psychedelics/ About Braxia Scientific Corp. Braxia Scientific is a...